However, given the aggressive nature of the neuro-2a neuroblastoma tumor model and how effective anti-CTLA4 treatment has been against idMMR neuroblastoma tumors, we anticipate a potentially effective response against orthotopic neuroblastoma tumors in renal capsules or metastatic disease in the bone marrow. This evidence concerns the gene CTLA4 and neuroblastoma.